Oral Dissolution Therapy for Gallstones: UDCA Guide
What is oral dissolution therapy?
Oral dissolution therapy is a non‑surgical treatment for cholesterol gallstones using ursodeoxycholic acid (UDCA), a naturally occurring bile acid. UDCA reduces cholesterol saturation in bile and gradually dissolves cholesterol stones over months. It is the only oral medication approved for gallstone dissolution. This therapy is not a cure – it requires a functioning gallbladder, and stones often recur after stopping treatment.
How UDCA dissolves cholesterol stones
UDCA works by several mechanisms:
- Reduces cholesterol secretion into bile: Lowers the cholesterol saturation index, making bile less lithogenic.
- Increases bile acid pool: UDCA becomes the predominant bile acid, improving cholesterol solubilisation.
- Promotes gradual dissolution of cholesterol crystals: Over months, the stone surface dissolves layer by layer.
UDCA does not affect pigment stones or calcified stones. It is ineffective if the gallbladder is non‑functioning (e.g., chronic cholecystitis).
Who is eligible for oral dissolution therapy?
Ideal candidates meet all of the following criteria:
- Small, radiolucent cholesterol stones (pigment or calcified stones not eligible).
- Stone diameter <5‑10 mm (best results for <5mm).
- Solitary stone (multiple stones have lower success).
- Functioning gallbladder (confirmed by ultrasound or HIDA scan).
- Mild or infrequent symptoms (not acute cholecystitis or pancreatitis).
- Patient unfit for surgery or refuses surgery.
Patients with obesity, rapid weight loss, or metabolic syndrome have lower success rates.
Success rates by stone characteristics
Based on clinical studies, complete dissolution rates at 12‑24 months:
| Stone characteristic | Complete dissolution rate | Time to dissolution |
|---|---|---|
| <5 mm, solitary, floating | 70‑90% | 3‑6 months |
| 5‑10 mm, solitary | 40‑60% | 6‑12 months |
| Multiple stones (>3) | 20‑40% | 12‑24 months |
| Calcified or pigment stones | 0% | Not indicated |
Duration, dosing, and monitoring
- Dose: 10‑15 mg/kg/day (typically 500‑600 mg daily in 2‑3 divided doses with meals).
- Duration: At least 6‑12 months. If stones are smaller at 6‑12 months, continue. If no reduction at 12 months, therapy is unlikely to succeed.
- Monitoring: Ultrasound at 6‑12 months to assess stone size. Complete dissolution is confirmed by ultrasound showing no stones. After dissolution, repeat ultrasound at 6 and 12 months to detect recurrence.
Recurrence after successful dissolution
Even after complete stone dissolution, the underlying metabolic abnormality persists. Recurrence rates:
- 5‑year recurrence: 30‑50%.
- 10‑year recurrence: 50‑70%.
- Higher recurrence in patients with obesity, multiple stones, or rapid weight loss.
To reduce recurrence, some doctors prescribe low‑dose UDCA (300 mg/day) long‑term, or recommend lifestyle changes (weight loss, low‑fat diet, regular meals). Many patients eventually require cholecystectomy.
Pros and cons vs surgery
- Pros of oral dissolution therapy:
- Non‑invasive, no anaesthesia, no incisions.
- Preserves the gallbladder (for patients who want to keep it).
- Can be used in patients unfit for surgery.
- Cons of oral dissolution therapy:
- Low success rates for stones >10mm.
- Requires months to years of medication.
- High recurrence rate (30‑50% at 5 years).
- Not suitable for pigment or calcified stones.
- Does not prevent acute cholecystitis or pancreatitis.
- Laparoscopic cholecystectomy:
- Definitive cure (removes the gallbladder, so no recurrence).
- High success rate (>95%).
- Low complication rate.
- Requires surgery and anaesthesia.
Interactive FAQ – Oral dissolution therapy
Yes, but success rates are lower (20‑40%). Multiple stones indicate a more aggressive lithogenic state, and recurrence after dissolution is very high.
A plain X‑ray (KUB) can show calcified (pigment) stones. Radiolucent stones may be cholesterol. The only definitive way is stone analysis after passage or removal.
Stopping early will not dissolve the stones. Partial dissolution may be lost, and stones can regrow. If you stop, consider cholecystectomy if you remain symptomatic.
UDCA is considered safe during breastfeeding. Very small amounts pass into breast milk, but no harm has been reported. Consult your doctor.
No known interaction. Oestrogen‑containing pills may increase gallstone risk, but UDCA does not interfere with their effectiveness.
UDCA costs approximately ₹1,500‑3,000 for a 6‑month course. Additional costs include periodic ultrasounds (₹500‑1,500 each).
Moderate alcohol is unlikely to interfere. Heavy drinking should be avoided as it can worsen liver disease, which may affect bile metabolism.
Yes – ursodeoxycholic acid is available as a generic medication in India under various brand names (Ursocol, Udiliv, etc.).
Yes – after ESWL fragmentation, UDCA is used to dissolve remaining fragments. This combination is occasionally used, but still has high recurrence.
Disclaimer: This information is for educational purposes. Oral dissolution therapy is not suitable for most patients. Consult a gastroenterologist at Vivekananda Hospital to determine if you are a candidate.